Clonidine Liquid Formulation Availability
Yes, clonidine is available in liquid formulations, including both an FDA-approved extended-release oral suspension and compounded oral liquids that can be prepared by pharmacies.
FDA-Approved Liquid Formulation
The most recent and clinically significant development is the clonidine extended-release (XR) oral suspension, which has been approved by the FDA for once-daily administration 1. This formulation:
- Is bioequivalent to the twice-daily clonidine XR tablets
- Provides "around-the-clock" effects with once-daily dosing
- Addresses a treatment gap as a liquid, once-daily, non-stimulant ADHD treatment option
- Demonstrates similar pharmacokinetic parameters to tablet formulations (Cmax, AUC within 80-125% bioequivalence range)
This represents a significant advancement over traditional tablet formulations, particularly for patients who have difficulty swallowing pills or require precise dose titration 2.
Compounded Liquid Formulations
For situations where the commercial oral suspension is unavailable or inappropriate, extemporaneously compounded clonidine oral liquids are well-established and stable 3, 4, 5:
- Concentration: Typically prepared at 0.01 mg/mL or 20 μg/mL (0.02 mg/mL)
- Vehicle: Ora-Blend or Simple Syrup, NF
- Stability: Maintains >90% potency for 91 days when stored at either room temperature (25°C) or refrigerated (4°C) in amber plastic bottles or clear plastic syringes 3, 4
- Preparation: Can be made from commercially available tablets ground and suspended in appropriate vehicle
Key Stability Data
The compounded suspensions demonstrate excellent chemical and physical stability 4:
- 99.2% of initial concentration retained at 25°C after 91 days
- 99.0% of initial concentration retained at 4°C after 91 days
- No changes in pH, color, taste, or precipitation observed
Clinical Context
Important consideration: While liquid formulations are mentioned as available for stimulants in ADHD treatment guidelines 2, clonidine as a non-stimulant has smaller effect sizes compared to stimulants and is generally considered second-line therapy. The liquid formulation is particularly valuable for:
- Pediatric patients unable to swallow tablets
- Precise dose titration (starting at 0.1 mg at bedtime, with careful uptitration)
- Patients with comorbid conditions where stimulants are contraindicated
Common Pitfalls to Avoid
- Do not confuse with the transdermal patch formulation (0.1,0.2,0.3 mg), which is also available but is not a liquid 2
- Monitor carefully for sedation/somnolence, hypotension, and bradycardia—frequent adverse effects that may be more pronounced with liquid formulations allowing rapid absorption
- Avoid abrupt discontinuation—taper gradually to prevent rebound hypertension
- Standard tablet formulations are 0.1,0.2, and 0.3 mg 6, not to be confused with liquid concentrations